Fluconaz 100mg Tablet (Fluconazole 100mg)

NAUSEA, ABDOMINAL PAIN, VOMITING, DIARRHOEA, FLATULENCE; ELEVATED LIVER FUNCTION VALUES; HEADACHE; RASH, EXFOLIATIVE DERMATITIS. RARELY, ANGIOEDEMA, ANAPHYLACTIC REACTIONS AND THROMBOCYTOPENIA. POTENTIALLY FATAL: HEPATOTOXICITY; RARELY ANAPHYLAXIS; STEVENS-JOHNSON SYNDROME.

RIFAMPICIN REDUCES FLUCONAZOLE LEVELS. REDUCES THEOPHYLLINE CLEARANCE. AFFECTS EFFICACY OF ORAL CONTRACEPTIVES. MAY INCREASE SERUM LEVELS OF ALPRAZOLAM, TRIAZOLAM, MIDAZOLAM, DIAZEPAM. MAY RAISE SERUM CONCENTRATIONS AND EFFICACY OF ORAL SULPHONYLUREAS, PHENYTOIN, CICLOSPORIN, CALCIUM CHANNEL BLOCKERS, TACROLIMUS, HMG-COA REDUCTASE INHIBITORS (EXCEPT PRAVASTAIN AND FLUVASTATIN), WARFARIN AND OTHER ANTICOAGULANTS. MAY REDUCE METABOLISM OF CAFFEINE. AVOID CONCURRENT USE WITH CLOPIDOGREL. POTENTIALLY FATAL: INCREASED RISK OF CARDIAC ARRHYTHMIAS WITH ASTEMIZOLE, CISAPIRIDE OR TERFENADINE.

HYPERSENSITIVITY.

FLUCONAZOLE DECREASES ERGOSTEROL SYNTHESIS BY INTERFERING WITH CYTOCHROME P450 ACTIVITY, THUS INHIBITING CELL MEMBRANE FORMATION OF SUSCEPTIBLE FUNGI INCLUDING B DERMATITIDIS, CANDIDA SPP, C IMMITIS, C NEOFORMANS, EPIDERMOPHYTON SPP, H CAPSULATUM, MYCOSPORUM SPP, TRICHOPHYTON SPP, THUS LEADING TO CELL DEATH. ABSORPTION: WELL ABSORBED AFTER ORAL ADMIN; PEAK PLASMA CONCENTRATIONS AFTER 1-2 HR (ORAL), MAY BE INCREASED WITH MULTIPLE DOSING. DISTRIBUTION: WIDELY DISTRIBUTED. PROTEIN-BINDING: 12%. EXCRETION: VIA URINE (80% AS UNCHANGED, 11% AS METABOLITES); 30 HR (ELIMINATION HALF-LIFE); INCREASED IN RENAL IMPAIRMENT. REMOVED BY DIALYSIS.

RENAL OR HEPATIC IMPAIRMENT. MAY PROLONG QT INTERVAL. PREGNANCY, LACTATION.